ATE409188T1 - Naphthyridinverbindungen - Google Patents

Naphthyridinverbindungen

Info

Publication number
ATE409188T1
ATE409188T1 AT06773519T AT06773519T ATE409188T1 AT E409188 T1 ATE409188 T1 AT E409188T1 AT 06773519 T AT06773519 T AT 06773519T AT 06773519 T AT06773519 T AT 06773519T AT E409188 T1 ATE409188 T1 AT E409188T1
Authority
AT
Austria
Prior art keywords
sub
naphthyridine compounds
histamine
receptor
serotonin
Prior art date
Application number
AT06773519T
Other languages
English (en)
Inventor
Michael LETAVIC
John Keith
Nicholas Carruthers
Chandravadan Shah
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE409188T1 publication Critical patent/ATE409188T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06773519T 2005-06-17 2006-06-16 Naphthyridinverbindungen ATE409188T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69200305P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ATE409188T1 true ATE409188T1 (de) 2008-10-15

Family

ID=37263777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06773519T ATE409188T1 (de) 2005-06-17 2006-06-16 Naphthyridinverbindungen

Country Status (14)

Country Link
US (1) US7417054B2 (de)
EP (1) EP1899334B1 (de)
JP (1) JP2008543880A (de)
CN (1) CN101243083A (de)
AT (1) ATE409188T1 (de)
AU (1) AU2006261162A1 (de)
CA (1) CA2612409A1 (de)
DE (1) DE602006002894D1 (de)
DK (1) DK1899334T3 (de)
ES (1) ES2314933T3 (de)
PL (1) PL1899334T3 (de)
PT (1) PT1899334E (de)
SI (1) SI1899334T1 (de)
WO (1) WO2006138714A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030078347A1 (en) * 2001-08-28 2003-04-24 General Electric Company Triazine compounds, polymers comprising triazine structural units, and method
DE602004019118D1 (de) * 2003-09-17 2009-03-05 Janssen Pharmaceutica Nv Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
CA2612495A1 (en) * 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7767666B2 (en) * 2006-06-29 2010-08-03 Janssen Pharmaceutica Nv Butyl and butynyl benzyl amine compounds
EP2046747A1 (de) * 2006-06-29 2009-04-15 Janssen Pharmaceutica N.V. Substituierte aminomethyl-benzamid-verbindungen
JP2009544579A (ja) * 2006-06-29 2009-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換ベンジルアミン化合物
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
US20080139564A1 (en) * 2006-11-16 2008-06-12 Keith John M Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators
CN101668746A (zh) 2007-03-01 2010-03-10 詹森药业有限公司 作为组胺h3受体调节剂的四氢异喹啉化合物
US7846930B2 (en) 2007-05-18 2010-12-07 Janssen Pharmaceutica Nv Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators
JP2011518127A (ja) * 2008-03-31 2011-06-23 エヴォテック・アクチエンゲゼルシャフト ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
JP5364327B2 (ja) * 2008-09-26 2013-12-11 富士フイルム株式会社 ハロピラジンカルボキサミド化合物の製造方法
WO2016089800A1 (en) * 2014-12-02 2016-06-09 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
CN113024456B (zh) * 2021-02-23 2022-05-13 江苏先导药业有限公司 一种2-氯烟酸的制备方法
WO2026030052A1 (en) 2024-07-31 2026-02-05 Fmc Corporation Fungicidal substituted azoles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH538477A (de) 1970-01-06 1973-06-30 Hoffmann La Roche Verfahren zur Herstellung von Isochinolin-Derivaten
GB1504424A (en) 1975-08-09 1978-03-22 Beecham Group Ltd Isoquinoline-derived aminoethers
GB1558043A (en) * 1976-02-03 1979-12-19 Onoda Cement Co Ltd Metal squeeze out tube and method and apparatus for forming a powder layer on its surface
EP0831829B1 (de) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
EP0978512A1 (de) 1998-07-29 2000-02-09 Societe Civile Bioprojet Aryloxy- (oder Arylthio)alkylamine ohne Imidazolring als Histamin-H3-Antagonisten und deren therapeutische Anwendung
NZ519146A (en) 1999-11-03 2004-02-27 Albany Molecular Res Inc 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
EP1113007A1 (de) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten
EP1595881A1 (de) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
DE602005026169D1 (de) * 2004-12-17 2011-03-10 Janssen Pharmaceutica Nv Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen

Also Published As

Publication number Publication date
AU2006261162A1 (en) 2006-12-28
PT1899334E (pt) 2008-11-06
EP1899334A2 (de) 2008-03-19
DK1899334T3 (da) 2008-11-24
JP2008543880A (ja) 2008-12-04
PL1899334T3 (pl) 2009-04-30
WO2006138714A3 (en) 2007-03-15
EP1899334B1 (de) 2008-09-24
SI1899334T1 (sl) 2009-04-30
ES2314933T3 (es) 2009-03-16
CN101243083A (zh) 2008-08-13
US7417054B2 (en) 2008-08-26
US20060287292A1 (en) 2006-12-21
WO2006138714A2 (en) 2006-12-28
DE602006002894D1 (de) 2008-11-06
CA2612409A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
SG146683A1 (en) Fused heterocyclic compounds as serotonin receptor modulators
DK1899334T3 (da) Naphthyridinforbindelser
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
ATE407927T1 (de) 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors
WO2008002820A3 (en) Substituted benzyl amine compounds
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
ZA200802010B (en) Pyrimidine compounds as serotonin receptor modulators
ATE461217T1 (de) Glp-1-verbindungen
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
AT9566U3 (de) Kopierfräseinrichtung zur herstellung von zahntechnischen werkstücken
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CR9365A (es) Compuestos y metodos para la inhibicion de la protein-cinasa raf
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
MY145305A (en) Cyclopropyl amines as modulators of the histamine h3 receptor
IS8530A (is) Meðferð á truflunum í auga þar með talinni sjóndepilsrýrnun
EP1931369A4 (de) Verfahren zum reduzieren der cd36-expression
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2008003659A1 (es) Compuestos derivados de 6-(4-bencilpiperazin-1-il)pirimidin-4-ona, moduladores de la enzima estearoil-coa-desaturasa 1; procedimiento de preparacion; composicin farmaceutica; y uso en el tratamiento y profilaxis de la obesidad.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
PL1692102T3 (pl) Kompozycje i sposoby do wykrywania i leczenia chorób i stanów związanych z receptorami chemokiny
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
SE0301650D0 (sv) Novel compounds
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1899334

Country of ref document: EP

REN Ceased due to non-payment of the annual fee